Study S001504
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial
Registration
Registered primary outcomes
- Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) [Week 0, Week 26]
Linked records (3)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0010237 | Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews | 2025 | Systematic review | PMID 39963952DOI | cites ClinicalTrials.gov:NCT01620489; registry reference DERIVED:39963952 |
| R0024805 | Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment. Zobel EH, Diabetes, obesity & metabolism | 2019 | Other trial | PMID 30663196DOI | registry reference RESULT:30663196 |
| R0026025 | Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Davies MJ, Diabetes care | 2016 | Randomized trial | PMID 26681713DOI | cites ClinicalTrials.gov:NCT01620489; registry reference RESULT:26681713 |